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The imbalance between reactive oxygen species production and antioxidant defenses leads to the condition known 
as oxidative stress. Disturbances in the normal redox status 
of tissues can cause toxic effects through the production of 
peroxides and free radicals that damage all cellular compo-
nents, including proteins, lipids, and DNA. Proteins are the 
main targets for reactive oxygen species that may alter every 
level of their structure from primary to quaternary, causing 
physical changes.1 Increased reactive oxygen species genera-
tion by vascular and inflammatory cells occurs in cardiovas-
cular disease, and there is widespread evidence that oxidative 
injury contributes to vascular damage and cardiac dysfunc-
tion.2 Elevated levels of oxidative biomarkers, such as protein 
carbonyls (PC) and lipid peroxidation markers (thiobarbi-
turic acid reactive substances, 8-epi-prostaglandin F), have 
been found in atherosclerotic lesions and in the circulation 
of patients with coronary artery disease (CAD).3–6 In plasma 
of patients with acute myocardial infarction (AMI) assayed 
within 24 to 96 hours after the acute event, an impaired fibrin 
lysis and an enhanced fibrinogen carbonylation has been 
recently observed.4,7
No evidence for a possible role of carbonylation on fibrino-
gen function in patients with post-AMI is available. Hence, 
for the first time, we investigated by an in vitro and an ex vivo 
approach, whether fibrinogen function—assessed by throm-
bin-catalyzed fibrin polymerization and fibrin susceptibility 
to plasmin-induced lysis—is associated with alterations in its 
oxidative status. Additional data on modifications in fibrino-
gen structure and in clot architecture are also reported.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
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Objective—Among plasma proteins, fibrinogen represents a major target of oxidative modifications. In patients with post–
acute myocardial infarction (6 months after the acute event), fibrinogen oxidation-induced carbonyls and fibrinogen 
function were estimated using in vitro and ex vivo approaches. Fibrinogen structural features and clot architecture were 
also explored.
Approach and Results—In 39 patients with post–acute myocardial infarction and 28 age-, sex-, and risk factor-matched 
controls, oxidative stress markers (in plasma and in purified fibrinogen fractions), thrombin-catalyzed fibrin polymerization, 
and plasmin-induced fibrin lysis were estimated. Circular dichroism spectra of purified fibrinogen extracts, electron 
microscopy, and differential interference contrast microscopy analyses of fibrin clots were also performed. Marked 
signs of oxidative stress in plasma (P<0.01 versus controls) and, correspondingly, an increased extent of fibrinogen 
carbonylation (3.5-fold over control values; P<0.01 versus controls) were observed in patients. Furthermore, fibrinogen 
fractions purified from patients exhibited significantly reduced clotting ability and decreased susceptibility to plasmin-
induced lysis (P<0.01 versus controls). Alterations in fibrinogen secondary structure, as suggested by circular dichroism 
spectroscopy, and in fibrin clot architecture, as analyzed by electron and differential interference contrast microscopy, 
were also identified.
Conclusions—Here, we report for the first time that patients with post–acute myocardial infarction present with an 
overall imbalance in redox status and marked fibrinogen carbonylation associated with altered fibrinogen function, thus 
suggesting a role for carbonylation as a direct mechanism of fibrinogen function. The observed features occur along with 
modifications in protein structure and in clot architecture.  (Arterioscler Thromb Vasc Biol. 2014;34:1355-1361.)
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Results
Subjects
Demographic and clinical characteristics of the population 
studied are summarized in Table 1.
Oxidative Stress Markers in Plasma  
and in Fibrinogen
As reported in Table 2, patient plasma displayed significantly 
higher total PC and thiobarbituric acid reactive substances lev-
els, and lower total antioxidant capacity, than healthy controls 
(P<0.05 versus controls). Plasma total PC was positively and 
significantly correlated with fibrinogen PC (P<0.05; R=0.555; 
Figure 1A) and with thiobarbituric acid reactive substances 
levels (P<0.05; R=0.444; Figure 1B).
Purified fibrinogen from patients displayed significantly 
increased carbonylation (3.5-fold) in comparison with healthy 
controls (P<0.01; Figure 1C). PC amounts obtained in human, 
2,2′-azobis(2-amidinopropane) dihydrochloride (AAPH)–
challenged purified fibrinogen (SIGMA, Milan, Italy) were 
comparable with those observed in fibrinogen from patients 
with post-AMI and resulted significantly increased compared 
with untreated fibrinogen (Table 3).
Circular Dichroism Spectra: Analysis 
of Secondary Structure
Secondary protein structure was analyzed by far-UV circu-
lar dichroism spectroscopy (Figure 2). In control subjects, 
the observed spectrum for fibrinogen suggested a typi-
cally α-helical structure with minima at 208 and at 222 nm. 
Fibrinogen from patients with post-AMI displayed an altered 
circular dichroism spectrum consisting mainly of a decrease 
in the negative peak in the 215 to 225 nm region, therefore, 
suggesting a decrease in α-helical content (Figure 2).
Fibrinogen Polymerization and Fibrin Formation
Representative curves of thrombin-catalyzed fibrinogen 
polymerization are shown in Figure 3. In an in vitro assay, 
increasing concentrations of AAPH affected thrombin-induced 
polymerization of pure fibrinogen (Figure 3A). In particular, 
in the presence of increasing AAPH concentrations, V
max
 and 
Max absorbance progressively and significantly decreased, 
whereas lag time increased in a dose-dependent manner 
(P<0.01 versus controls).
To evaluate whether an antioxidant treatment could prevent 
the observed alterations, 0.05 mmol/L Trolox was added to the 
AAPH incubation reactions and thrombin-catalyzed polym-
erization of fibrinogen was performed. As Figure 3A reports, 
the simultaneous incubation of AAPH with Trolox was able to 
prevent the observed changes.
Similarly, in patients, the ability of fibrinogen to undergo 
clotting was diminished: significant differences in lag time, 
V
max
, and Max absorbance versus controls were found 
(P<0.01; Figure 3B). In Figure 3C, the correlation analysis 
between fibrinogen carbonyl content and Max absorbance 
was reported: the relationship seems inverse and significant 
(P<0.05 R=0.419).
Transmission Electron Micrographs and 
Differential Interference Contrast Microscopy
Using electron microscopy, we found that fibrin filaments 
from patients and controls examined preplasmin digestion 
displayed differences in size and morphology: in particu-
lar, control fibrin filaments seemed as bundles of densely 
packed, longitudinally arranged fibrin molecules (Figure 4A, 
top), whereas post-AMI fibrin filaments consisted of thinner 
fibrin fibers (mean diameter, 120±13.2 nm versus control, 
151±13.6 nm; Figure 4B). After plasmin digestion, samples 
from control subjects showed a complete disarrangement of 
fibrin filaments, with short fibrin monomers forming a loose 
3-dimensional network (Figure 4A, lower left). Samples from 
patients with post-AMI after plasmin digestion still showed a 
filamentous pattern although with slightly decreased average 
fiber size (mean diameter, 89±10.9 nm versus control 40±3.7 
Nonstandard Abbreviations and Acronyms
AAPH 2,2′-azobis(2-amidinopropane) dihydrochloride
AMI acute myocardial infarction
CAD coronary artery disease
PC protein carbonyls
Table 1. Clinical Characteristics of Post–Acute Myocardial 
Infarction Patients and Control Subjects
Patients (n=39) Controls (n=28) P Value
Men/Women (n, %) 27/12 (69.2) 20/8 (67.9) 0.999
Age, y; median and  
interquartile range
71.0 (59–77) 69.8 (58–78) 0.845
Hypertension (n, %) 26 (66.7) 18 (59.2) 0.999
Smoking habit (n, %) 9 (23.1) 6 (21.4) 0.777
Dyslipidemia (n, %) 18 (46.2) 12 (33.9) 0.809
Diabetes mellitus (n, %) 11 (28.2) 5 (17.9) 0.393
Family history of CAD (n, %) 19 (48.7) 4 (14.2) 0.004
Overweight (n, %) 8 (20.5) 6 (18) 0.759
ACE-inhibitors (n, %) 27 (69.2) 10 (35.7) 0.012
Statins (n, %) 24 (61.5) 11 (39.3) 0.087
Proton pump inhibitors (n, %) 37 (94.9) 1 (3.5) <0.001
β-Blockers (n, %) 34 (87.2) 10 (35.7) <0.001
ACE indicates angiotensin-converting enzyme; and CAD, coronary artery 
disease.
Table 2. Plasma Redox Status and Fibrinogen Carbonyl 
Content in Patients With Post-AMI and Control Subjects
Control Subjects Patients With Post-AMI 
TBARS, nmol/mL 11.2±3.3 30.5±13.6* (28.90)
TAC, nmol/mL 470.2±45.3 306.9±98.7* (292.0)
Total PC plasma, nmol/mg 1.15±0.31 2.87±1.02* (2.73)
Fibrinogen carbonyl  
content, nmol/mg
0.19±0.05 0.66±0.32* (0.69)
All data are represented as mean±SD. PC indicates protein carbonyls; post-
AMI, post–acute myocardial infarction; TAC, total antioxidant capacity; and 
TBARS, thiobarbituric acid reactive substance.
*Statistically significant difference vs Control at the P<0.05 level, as assessed 
using the ANOVA-Bonferroni test.
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nm; Figure 4B) and evident fibrin monomers (Figure 4A, 
lower right).
In Figure 4A, fibrin samples obtained from patients with 
post-AMI and controls analyzed by differential interference 
contrast microscopy are shown. A tight fibrin network is still 
evident after plasmin-induced lysis in fibrin obtained from 
patients with post-AMI when compared with that obtained 
from controls.
Fibrin Susceptibility to Plasmin-Induced Lysis
Fibrin β-chain degradation at 0, 3, and 6 hours after plasmin 
digestion in vitro experiments consisting of human purified 
fibrinogen treated with AAPH (in the absence or presence of 
Trolox) and quantification of residual β-chain intensity after 6 
hours plasmin digestion is reported in Figure 5A. Fibrin clots 
obtained with pure fibrinogen after incubation with increas-
ing AAPH concentrations showed reduced susceptibility to 
plasmin-induced lysis, at each considered time of plasmin 
digestion. To evaluate whether an antioxidant treatment could 
prevent the observed alterations, 0.05 mmol/L Trolox was 
added to AAPH incubation reactions and fibrin susceptibil-
ity to plasmin-induced lysis was then assessed. As shown in 
Figure 5A, the simultaneous incubation of AAPH and Trolox 
was able to prevent the observed changes in fibrin digestion 
by plasmin.
Fibrin β-chain degradation after 0, 3, and 6 hours of plasmin 
digestion in patients with post-AMI and controls is reported in 
Figure 5B. In patients with post-AMI, the relative band inten-
sity at each considered time of plasmin digestion was signifi-
cantly higher with respect to controls.
In patients, the correlation between fibrinogen carbonyl 
content and the relative fibrin β-chain intensity after 6 hours 
of plasmin digestion was shown to be positive and signifi-
cant (P<0.05; Figure 5C). In patients with post-AMI, fibrin 
β-chain intensity after 6 hours of plasmin digestion was also 
significantly correlated with plasma PC (P<0.01; R=0.540) 
and thiobarbituric acid reactive substances levels (P<0.01; 
R=0.616, data not shown).
Discussion
The results of the present study show, for the first time, that 
in patients with post-AMI (1) a systemic redox imbalance is 
coupled with an increased level of fibrinogen carbonylation; 
(2) changes in the secondary protein structure of fibrinogen 
are present; (3) the increased extent of fibrinogen carbonyl-
ation is associated with altered polymerization and suscepti-
bility to plasmin-induced lysis; and (4) marked modifications 
in the global clot architecture are evident.
Atherosclerosis is characterized by lipid and protein oxida-
tion in the vascular wall that contributes to important clinical 
manifestations of CAD represented by plaque disruption and 
endothelial dysfunction.2,8
Increased levels of oxidative biomarkers and decreased 
antioxidant activity in the circulating blood of patients with 
CAD have been reported,9,10 whereas raised PC values have 
also been found in patients with myocardial infarction, pro-
viding further evidence for enhanced oxidative stress in these 
subjects.11
Figure 1. Pearson rank correlation analysis in patients with 
post–acute myocardial infarction (AMI) comparing plasma 
total protein carbonyls (PC) and fibrinogen carbonyl con-
tent (P<0.05; R=0.555; A) and comparing plasma total PC 
and thiobarbituric acid reactive substance (TBARS) levels 
(P<0.05; R=0.444; B). Fibrinogen carbonyl content in purified 
fibrinogen fractions from patients with post-AMI (n=39) and 
controls (n=28; C). Protein carbonyl content was measured 
as described in the Materials and Methods in the online-only 
Data Supplement. All experiments were performed by running 
each sample in triplicate. Values are represented as mean±SD. 
*Significant difference vs control at the P<0.01 level (ANOVA-
Bonferroni test).
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In the present study, both plasma PC and fibrinogen PC 
were markedly and significantly increased in patients with 
post-AMI when compared with control subjects and were 
significantly correlated. In this context, previous reports indi-
cate that fibrinogen is more susceptible to oxidation than most 
other plasma proteins;12 in particular, fibrinogen is 20× more 
susceptible to oxidation than albumin,13 as also reported in 
patients with MI, where it was found that total plasma carbon-
yls were formed preferentially on fibrinogen.7
When we investigated, using far-UV circular dichroism 
spectroscopy, whether the alterations observed in fibrinogen 
functions could be related to secondary structure modifications, 
we found a shift in the mean residual ellipticity and a reduc-
tion in α-helical content in patients with post-AMI in compari-
son with controls, suggesting a change in secondary structure 
content. Taking into consideration that secondary structure of 
proteins plays a major role in determining their functionality in 
specific physiological processes, this preliminary result needs 
further investigation and leads to speculation that carbonyl-
ation promotes the formation of a less α-helix–rich species.14
In our study, the relationship between oxidized fibrinogen 
and fibrinogen function has been explored by measuring the 
clotting ability of purified fibrinogen using an in vitro throm-
bin-catalyzed polymerization assay. In this system, the mag-
nitude of the turbidity increase relates to the architecture of 
the formed clot; the altered maximum absorbance of fibrin 
polymerization reflects the formation of thinner and more 
compact fibers.15
Interestingly, the functional alterations that we observed 
when fibrinogen was subjected to oxidation could easily be 
reversed by simultaneous treatment with a water soluble ana-
logue of α-tocopherol (Trolox), emphasizing the role of oxi-
dative modification of fibrinogen on its function.16
In patients with post-AMI, we observed a slower rate of 
thrombin-catalyzed fibrinogen polymerization; this alteration 
in fibrinogen function was found to be directly and signifi-
cantly correlated to fibrinogen carbonyl content, suggesting an 
influence of carbonylation on thrombin-induced polymeriza-
tion of fibrinogen.
The introduction of carbonyl groups into proteins can be 
triggered by different reactive oxygen species or secondary by-
products of oxidative stress and can arise at different sites and 
by different mechanisms.17 Carbonylation can result in several 
different protein modifications, which may specifically affect 
the biological activity of proteins.18 Among the functional 
effects that have been described, modified binding activities, 
enzyme inactivation, and altered susceptibility to proteolytic 
degradation are the most represented.19 It has been shown 
that the introduction of carbonyl derivatives (aldehydes and 
ketones) may alter the conformation of the polypeptide chain, 
thus determining functional modification of proteins.20 The 2 
amino acids that are perhaps the most prone to oxidative attack 
are cysteine and methionine, both of which contain susceptible 
sulfur atoms. Other amino acyl moieties, especially lysine, 
arginine, proline, and threonine, incur formation of carbonyl 
groups on the side chains.21 The presence of oxidizable amino 
acids (Pro and Arg) in the cleavage site of thrombin, or the 
cleavage of peptide bonds by oxidation of glutamyl residues, 
may explain the altered thrombin-induced fibrin polymeriza-
tion observed in patients with post-AMI.
In a recent in-depth study of the thrombin cleavage site, the 
authors show that mutating both Pro and Arg results in a 200- 
to 400-fold drop in cleavage, which highlights the importance 
of these 2 positions for maximal substrate cleavage.22
In our experimental model, carbonylation of purified human 
fibrinogen was responsible for an oxidant-dependent decrease 
in thrombin-induced clot formation likely determined by a 
covalent protein modification. In line with this, the observed 
alteration in clotting ability of purified human fibrinogen was 
completely prevented when it was incubated with both the 
oxidant generator AAPH and the antioxidant Trolox.
Our findings showing alteration of fibrinogen function 
strengthen other reports, showing that fibrinogen oxidation 
impairs the capacity of isolated fibrinogen to form a fibrin clot 
under the effect of thrombin16; these results seem to contrast 
with those reported by Paton et al,7 obtained in 12 patients with 
MI, which were performed in the acute phase of myocardial 
infarction (ie, within 24–96 hours of the acute event). This dis-
crepancy could be because of the different clinical setting: the 
Figure 2. Spectroscopy analysis of fibrinogen secondary struc-
ture. Representative far-UV circular dichroism spectra of fibrino-
gen purified from a patient with post–acute myocardial infarction 
(AMI) and a control subject. Spectroscopic analyses were per-
formed as described in the Materials and Methods in the online-
only Data Supplement.
Table 3. In vitro Assay: Protein Carbonyl Content in AAPH-Treated Pure Fibrinogen
Untreated 0.01 mmol/L AAPH 0.05 mmol/L AAPH 0.1 mmol/L AAPH 1 mmol/L AAPH
Pure fibrinogen carbonyl 
content, nmol/mg
0.1±0.02 0.41±0.12* 1.22±0.22* 2.09±0.41* 9.19±1.32*
All data are represented as mean±SD. AAPH indicates 2′-azobis(2-amidinopropane) dihydrochloride.
*Statistically significant difference vs untreated at the P<0.05 level, as assessed using the ANOVA-Bonferroni test.
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acute phase is characterized by an inflammatory and hyper-
coagulable state in which molecular alteration of fibrinogen 
because of fibrinopeptide A release was demonstrated.23
Accordingly, a clear difference related to the clinical phase 
of CAD was documented by Undas et al,4 who reported signifi-
cant differences in fibrinogen/fibrin alterations between patients 
with acute coronary syndrome and patients with stable angina.
To establish another important aspect of fibrinogen func-
tion in relation to carbonylation, we estimated fibrin resistance 
to plasmin-induced lysis.24 We confirmed that in patients with 
post-AMI, fibrin is resistant to lysis and that its degradation is 
significantly lowered with respect to healthy controls.25 Our 
results agree with previous investigations, demonstrating that 
patients with premature CAD produce abnormal plasma fibrin 
clots ex vivo that are resistant to fibrinolysis.26
Interestingly, one of our main results is a strong and posi-
tive correlation between fibrinogen PC and residual β-chain 
intensity after plasmin-induced lysis. A similar correlation 
was found when correlating residual β-chain intensity after 
plasmin-induced lysis with plasma PC. The reported find-
ings are consistent with the observation that F2-isoprostanes, 
which are stable markers of oxidative stress, are associated 
with reduced clot permeability and fibrinolysis in patients 
with cardiovascular.4
Figure 3. Representative curves of thrombin-catalyzed fibrino-
gen polymerization and corresponding lag time, Vmax, and Max 
absorbance in purified human fibrinogen (Fg; Sigma, Milan, Italy) 
incubated with increasing concentrations of the peroxyl radical 
generator 2,2′-azobis(2-amidinopropane) dihydrochloride (AAPH; A) 
and in Fg purified from patients with post–acute myocardial infarc-
tion (AMI) and controls (B). AAPH treatment protocol (in the absence 
or presence of the antioxidant Trolox) and thrombin-catalyzed fibrin 
polymerization were performed as described in the Materials and 
Methods in the online-only Data Supplement. Values are reported as 
mean±SD of 3 independent experiments performed in triplicate (ie, 
each sample run in triplicate; A) and of 3 independent experiments 
performed on 39 patients with post-AMI and 28 controls (B). *Sig-
nificant difference vs control at the P<0.01 level (ANOVA-Bonferroni 
test). In patients with post-AMI, Pearson rank correlation analysis 
comparing post-AMI Fg carbonyl content and Max absorbance 
showed a statistical significance (C; P<0.05; R=0.419).
Figure 4. Representative transmission electron microscopy and 
differential interference contrast (DIC) microscopy images of fibrin 
from a patient with post–acute myocardial infarction (AMI) and a 
control subject (A). The same fibrinogen concentration was used 
in these subjects, who were matched for age and sex. Three 
different samples were analyzed, with 10 different clot areas 
sampled. Transmission Electron and DIC microscopy analyses 
were performed as described in the Materials and Methods in 
the online-only Data Supplement. The mean diameter of fibrin 
filaments from the different experimental groups was measured 
by computer-aided morphometry on ×50 000 transmission elec-
tron micrographs, using the freely available ImageJ 1.33 image 
analysis program (http://rsb.info.nih.gov/ij). For each sample, ≥50 
filaments were measured and the values reported as mean±SD 
(B). *Significant difference vs control before plasmin digestion 
(P<0.01; ANOVA-Bonferroni test). #Significant difference vs post-
AMI before plasmin digestion (P<0.01; ANOVA-Bonferroni test).
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Moving from the finding of altered thrombin-induced fibrin 
polymerization, possibly characterized by the presence of 
impaired lateral association of protofibrils and by alteration 
in fiber size resulting from fibrinogen carbonylation, we then 
performed an in-detail analysis of clot structure by electron 
and differential interference contrast microscopy. Our main 
finding relates to the presence, in post-AMI fibrin, of a tight 
fibrin network composed of filaments with slightly decreased 
average fiber size that are resistant to plasmin-induced lysis 
when compared with control subjects. Actually, clot structure 
is determined by several factors.27,28 In most purified systems, 
as fiber size increases, pore size increases too. Fibrin networks 
composed of thin fiber strands have small pores and are more 
rigid and less permeable. In contrast, clots formed by thick 
fiber strands have large liquid spaces, which imply higher 
permeability and accelerated fibrinolysis, likely because of a 
more efficient transport of fibrinolytic agents through a fibrin 
clot.29 Clots composed of thin fibers and small pores are more 
thrombogenic and are associated with CAD.30–32 The mecha-
nisms underlying formation of these abnormal fibrin clots 
have not yet been elucidated but could be related to post-trans-
lational modifications of fibrinogen.33 The data presented here 
suggest a causative link between fibrinogen carbonylation and 
the structural alterations observed in patients with post-AMI.
An interesting aspect that must be taken into consideration 
is that all patients enrolled in the study were given aspirin as a 
secondary prevention treatment strategy, which could also have 
had an effect on clot architecture. Fibrinogen, in fact, is rich 
in lysine residues, which are the main target of acetylation by 
aspirin, treatment with which may disturb charge distribution 
on the protein surface. This action, however, has been shown to 
not affect the rate of fibrinogen gelation by thrombin.34
In conclusion, our in vitro and ex vivo findings show that 
in patients with post-AMI, an overall imbalance in redox 
status and marked fibrinogen carbonylation are associated 
with altered clotting activity and susceptibility of plasmin to 
lysis. These features, observed far from the acute event, are 
accompanied by an alteration in protein structure and clot 
architecture.
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Fibrinogen represents an important target of oxidative modifications. In patients with post–myocardial infarction (6 months after the acute 
event), an overall imbalance in plasma redox status and marked fibrinogen carbonylation were associated with impaired clotting activity and 
reduced plasmin susceptibility to lysis. Fibrinogen protein secondary structure and clot architecture were also markedly altered. The features 
described here, observed far from the acute event, provide new insights into the mechanisms that control fibrin structure and function. These 
new findings might allow the development of pharmaceutical strategies to modulate fibrin structure in vivo and thereby might be useful for 
the primary and secondary prevention of coronary artery disease.
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